Investment Rating - The report indicates a positive outlook on the Chinese innovative drug industry chain, with a focus on business development (BD), policy, and clinical advancements [1]. Core Insights - The innovative drug BD authorization total exceeded $60 billion in Q1 2026, reflecting accelerated global cooperation value [2][11]. - The Chinese government has upgraded its strategic positioning of the biopharmaceutical industry, marking it as a "new emerging pillar industry" in the 2026 government work report [2][15]. - Clinical activity is on the rise, with Chinese innovative drug R&D entering a high-quality harvest period, as evidenced by a significant increase in the number of innovative drugs entering clinical trials and being approved for market [2][16][19]. Market Observation - The pharmaceutical and biotechnology sector rose by 1.56% this week, ranking 4th out of 31 sectors, while it has seen a year-to-date decline of 1.38%, ranking 17th [1][10]. Industry Dynamics - In 2025, the total transaction amount for Chinese innovative drug BD reached a historical high of $135.655 billion, with 157 transactions, and the first quarter of 2026 has already seen over $60 billion in transactions [2][11]. - The first version of the commercial health insurance innovative drug catalog was officially launched, enhancing the multi-layered payment system for innovative drugs [2][15]. - By the end of 2025, China accounted for 33.7% of the global innovative drugs in development, leading the world, with 827 innovative drugs entering clinical trials for the first time [2][16][19]. Company Dynamics - **Insilico Medicine**: Announced a collaboration with Eli Lilly, with an upfront payment of $115 million and a total deal value of up to $2.75 billion, validating the commercial potential of its AI drug development platform [3][23]. - **Kangfang Biopharma**: Achieved revenue of 3.056 billion yuan in 2025, a year-on-year increase of 43.9%, driven by core dual-antibody products [3][24]. - **Innovent Biologics**: Reported total revenue of 13.042 billion yuan in 2025, a 38.4% increase, marking its first year of profitability with a significant growth in product revenue [3][25]. - **Kolin Biotech**: Generated revenue of 2.058 billion yuan in 2025, with a focus on the commercialization of its core ADC products [3][26]. - **Ascletis Pharma**: Achieved record revenue of 7.731 billion yuan in 2025, with innovative drugs accounting for 81.5% of total revenue [3][27]. - **Zai Lab**: Reported revenue of 269.6 million yuan in 2025, with a strong cash reserve of 919 million yuan, supporting its global expansion plans [3][28].

Investment Rating - The report maintains a positive outlook on the Chinese innovative drug industry chain, highlighting the potential for growth driven by business development (BD), policy support, and clinical advancements [1]. Core Insights - The innovative drug BD authorization total exceeded $60 billion in Q1 2026, indicating accelerated realization of global collaboration value. In 2025, the total transaction amount for Chinese innovative drug BD reached a historical high of $135.655 billion, with 157 transactions [2][11]. - The government has upgraded its strategic positioning of the biopharmaceutical sector, now recognized as a "new emerging pillar industry" in the 2026 government work report. This includes the establishment of a multi-layered payment system for innovative drugs [2][15]. - Clinical activity is on the rise, with China leading globally in the number of innovative drugs under development, accounting for 33.7% of the total. By the end of 2025, 827 original innovative drugs entered clinical trials, representing 47.4% of the global total [2][16][19]. Market Observation - The pharmaceutical and biotechnology sector saw a weekly increase of 1.56%, ranking 4th out of 31 sectors, while year-to-date, the sector has declined by 1.38%, ranking 17th [1][10]. Company Dynamics - **Insilico Medicine**: Announced a collaboration with Eli Lilly, with an upfront payment of $115 million and a total deal value potentially reaching $2.75 billion, validating the commercial value of its AI drug development platform [3][23]. - **Kangfang Biopharma**: Reported a revenue of 3.056 billion yuan in 2025, a 43.9% increase year-on-year, driven by the commercialization of its core dual-antibody products [3][24]. - **Innovent Biologics**: Achieved a total revenue of 13.042 billion yuan in 2025, a 38.4% increase, marking its first time surpassing 10 billion yuan in revenue and returning to profitability [3][25]. - **Kolin Biotech**: Generated revenue of 2.058 billion yuan in 2025, a 6.5% increase, with its core ADC product contributing to its commercial growth [3][26]. - **Ascletis Pharma**: Reported a total revenue of 7.731 billion yuan in 2025, a 16.5% increase, with innovative drugs accounting for 81.5% of its revenue [3][27]. - **Zymeworks**: Achieved revenue of 269.6 million yuan in 2025, with a strong cash reserve of 919 million yuan, supporting its global expansion plans [3][28].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved a revenue of 2.058 billion yuan in 2025, representing a year-on-year growth of 6.5%. The revenue from drug sales significantly increased by 949.8% to 543 million yuan, while income from licensing and cooperation agreements decreased by 19.6% to 1.498 billion yuan. The net profit attributable to shareholders was -382 million yuan, a decline of 43.2% year-on-year, primarily due to increased sales expenses related to the expansion of the commercialization team and marketing activities [5][6] - The company has adjusted its revenue forecasts for 2026 to 2028 to 2.230 billion yuan, 4.179 billion yuan, and 6.647 billion yuan respectively, down from previous estimates. The current stock price corresponds to a price-to-earnings ratio of -175.5 for 2026, 234.8 for 2027, and 52.8 for 2028. The long-term development of the company is viewed positively due to the clear trend of commercialization and multiple products being included in the national medical insurance catalog [5][6] Financial Summary - In 2025, the company reported a revenue of 2.058 billion yuan, with a year-on-year growth of 6.5%. The projected revenues for 2026, 2027, and 2028 are 2.230 billion yuan, 4.179 billion yuan, and 6.647 billion yuan respectively, indicating a growth trajectory [8] - The net profit is expected to be -639 million yuan in 2026, with a significant recovery projected in 2027 to 478 million yuan and further growth to 2.124 billion yuan in 2028. The gross margin is expected to be 66.2% in 2026, improving to 82.7% by 2028 [8][10] - The company has a total market capitalization of 99.291 billion HKD and a circulating market capitalization of 69.307 billion HKD, with a current stock price of 425.80 HKD [1][8] Product and Market Development - The core product, sac-TMT, has received approval for multiple indications and is expected to see significant sales growth in 2026. The company has successfully included sac-TMT, Tagolizumab, and Westimab N01 in the new national medical insurance catalog, which is anticipated to drive rapid sales growth [6] - The company has established a commercialization team of over 600 people, covering more than 1,200 hospitals, which lays a solid foundation for product sales. Additionally, sac-TMT has received approvals for new indications, enhancing its market potential [6][7]

Investment Rating - The report maintains a "Buy" rating for Keren Biotechnology (06990), indicating a positive outlook for the company as it is positioned to become a leading global ADC enterprise due to its differentiated ADC pipeline, strong R&D foundation, and deep collaboration with Merck [1] Core Insights - Keren Biotechnology's core product, sac-TMT (Lukangshatuo), is identified as the main growth driver for the company, with significant clinical advantages demonstrated in key studies [1] - The product has shown a progression-free survival (PFS) of 7.9 months compared to 2.8 months for chemotherapy (HR=0.23) and an overall survival (OS) of 20 months compared to 11.2 months for chemotherapy (HR=0.45), indicating its competitive edge in the market [1] - The company expects substantial sales growth for sac-TMT in 2026, especially after its inclusion in the national medical insurance directory, with projections indicating that this product will contribute over 80% of revenue [1] Clinical Development - 2026 is highlighted as a critical year for Keren Biotechnology, with a focus on the ongoing Phase III clinical trials of sac-TMT combined with Pembrolizumab (Keytruda) for first-line treatment of non-small cell lung cancer, with key data expected to be released throughout the year [2] - The company has already achieved primary endpoints in its Phase III study for PD-L1 positive non-small cell lung cancer, reinforcing confidence in the clinical value of the ADC + IO combination [2] - Keren Biotechnology is also advancing other ADC pipelines and combinations with immunotherapies and small molecule targeted therapies to expand indications [2] Competitive Advantages and Innovation - Keren Biotechnology has established collaborations with Merck for several ADC projects, including SKB410 and SKB571, which have shown significant progress in a competitive landscape [3] - The company is exploring diverse technological pathways, including RDC and dual payload ADCs, with several innovative products already in clinical stages [3] - Notable projects include SKB107 for advanced solid tumors, SKB103 as a dual-target ADC, and SKB565, which introduces a new concept of dual delivery for enhanced anti-tumor effects [3] Long-term Growth Potential - Keren Biotechnology is expected to continue unlocking pipeline value and driving long-term growth by leveraging its ADC technology advantages and global collaborations with international pharmaceutical companies like Merck [4]

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry [5] Core Viewpoints - Short-term fluctuations do not change the long-term growth trajectory of the innovative drug sector. Despite recent market volatility, the underlying logic for medium to long-term growth remains intact, driven by globalization, technological breakthroughs, and industry upgrades [8][12] - The focus has shifted from "can we go global" to "what progress has been made after going global," emphasizing the importance of overseas clinical deployment and milestone achievements for innovative drugs [13][14] - Breakthroughs in frontier technologies, particularly in small nucleic acids and CAR-T therapies, position Chinese companies to become core global assets [18][20] - The commercialization of innovative drugs is expected to lead to a profitability inflection point, with key companies entering a positive cycle of product volume growth and reinvestment in R&D [22] Summary by Sections 1. Short-term Fluctuations, Long-term Growth - The innovative drug sector has experienced significant volatility due to concentrated expectations and emotions, but the long-term growth trend remains unchanged [8][12] - The valuation of leading companies has reached reasonable levels, suggesting potential investment opportunities as market sentiment stabilizes [12] 1.1 Focus on Globalization Progress - The emphasis has shifted to the progress of products in overseas clinical trials, with a focus on key data readouts and milestone achievements [13][14] - Domestic bispecific antibodies are accelerating their global clinical trials, becoming core trading assets in the context of expiring patents for PD-(L)1 products [13] 1.2 Breakthroughs in Frontier Technologies - Chinese companies are leading in small nucleic acids and CAR-T therapies, with significant advancements in delivery technologies expanding treatment options beyond rare diseases [18] - In vivo CAR-T therapies have shown preliminary clinical effectiveness, with a growing number of transactions indicating a shift towards mainstream adoption [20] 1.3 Commercialization Driving Profitability - Leading innovative drug companies are entering a cycle of product volume growth that supports R&D reinvestment, with expectations for exceeding market performance in 2023 [22] - The upcoming earnings period in March-April 2026 is seen as a critical validation point for the sector [22] 2. Global New Drugs: Highlights in Autoimmunity and Oncology - The report highlights the approval of the world's first PD-L1/TGF-β bispecific antibody, showcasing the R&D capabilities of domestic companies [26][27] - The successful launch of innovative drugs in critical therapeutic areas reflects the growing strength of domestic pharmaceutical companies in addressing unmet medical needs [26][27]

Group 1 - The core issue highlighted is the current burden of innovative drug costs, where basic medical insurance covers 44%, commercial insurance covers 7%, and nearly half is borne by patients themselves [1] - The new policies since 2026 have significantly empowered the innovative drug industry, optimizing the payment system and enhancing drug accessibility [1][2] - The 2025 updated national medical insurance drug list represents the largest expansion of innovative drugs since the inception of the list, adding 114 new drugs while removing 29 [2] Group 2 - The newly added drugs are characterized by filling clinical gaps, superior efficacy, and cost-effectiveness, addressing unmet treatment needs [2] - The first commercial insurance innovative drug list includes 19 drugs, marking a significant step in supporting innovative drugs within a multi-tiered medical insurance system [2][3] - The new policies are expected to reshape the retail drug ecosystem, enhancing the accessibility and efficiency of innovative drugs [4][5] Group 3 - The innovative drug market is anticipated to undergo a restructuring, with deeper integration between innovative drug companies and retail pharmacies [5] - The dual-channel management mechanism for negotiated drugs aims to solve the "last mile" issue in drug accessibility [4][6] - The support from the medical insurance fund has exceeded 460 billion yuan, benefiting 1 billion patients and driving sales of related drugs over 670 billion yuan [7] Group 4 - The current period is seen as a golden era for high-quality development in the innovative drug industry, with increasing support for research and development from the government [8] - The alignment of national medical needs with corporate innovation is crucial for ensuring that innovative results reach patients more quickly and broadly [8][9] - Continuous efforts in basic research and supportive industrial policies are necessary for maintaining a leading position in global pharmaceutical innovation [9]

Core Viewpoint - The Hong Kong stock market's innovative drug ETF (159570) is experiencing a pullback, with several key stocks in the index declining significantly, indicating a potential shift in market sentiment towards the innovative pharmaceutical sector [1][4]. Group 1: Market Performance - As of 11:07, major stocks in the Hong Kong innovative drug ETF have mostly retreated, with notable declines: CSPC Pharmaceutical down over 5%, China Biologic Products down over 3%, and Innovent Biologics down over 4% [1]. - The ETF opened with a gain of over 2% but later experienced a decline of 0.62%, with trading volume surpassing 700 million HKD, indicating active market participation despite the pullback [4]. - The ETF has seen a net inflow of over 340 million HKD in the past five days, with its latest scale exceeding 25.2 billion HKD, leading among similar funds [4]. Group 2: Industry Developments - The innovative drug business development (BD) remains robust, with companies like Rego Biopharma and Qinhai Biotech making significant strides, and the total upfront payment for innovative drug BD transactions in China exceeding one-third of the total for 2025 by mid-February [3]. - Key innovative drug pipelines have achieved milestones overseas, such as CSPC's SYH2053 entering Phase III trials and Hanmi Pharmaceutical's approval for marketing in the EU [3]. - The FDA has reformed its drug approval policy, allowing a single pivotal trial plus confirmatory evidence as the default standard for new drug approvals, which is expected to enhance efficiency and reduce costs in drug development [6][9]. Group 3: Regulatory Changes - The National Health Commission has revised the essential drug catalog management measures for the first time in 11 years, indicating potential changes in the essential drug catalog and signaling a more rational policy environment [5]. - The overall atmosphere for drug procurement has been stable, with high rates of contract renewals and a focus on quality and pricing, reflecting a shift towards more rational procurement practices [5]. Group 4: ETF Composition - The Hong Kong innovative drug ETF (159570) is fully invested in innovative drugs, with the top ten constituent stocks accounting for over 74% of the index, highlighting its concentrated exposure to leading companies in the sector [10]. - The ETF has shown a significant increase of over 90% year-to-date, outperforming other indices in the Hong Kong pharmaceutical sector [11][12].

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [1] Core Insights - The A-share innovative drug sector saw a decline of 1.32% this week, outperforming the CSI 300 index by 0.02 percentage points, while the biopharmaceutical sector rose by 0.04% [2][14] - The Hong Kong innovative drug sector decreased by 1.45%, outperforming the Hang Seng Index by 1.57 percentage points [19] - The XBI index in the US increased by 0.64%, with a cumulative increase of 47.35% over the past six months [3][19] Summary by Sections A-share and Hong Kong Innovative Drug Sector Performance - A total of 56 stocks rose and 88 stocks fell in the innovative drug sector across mainland China and Hong Kong [2] - The top three gainers were China Antibody-B (+22.79%), Yiteng Jiahe (+14.00%), and Nuocheng Jianhua (+12.24%) [2][13] - The bottom three performers were Yaojie Ankang-B (-14.58%), Shuanglu Pharmaceutical (-13.95%), and Xin Nuowei (-12.53%) [2][13] Recent Approvals and Clinical Trials - In February, four innovative drugs were approved for market in China, with no new indications approved [4][22] - In the US, one NDA was approved, with no BLA approvals reported [5][40] - No innovative drugs were approved in Europe or Japan during this period [5][29][34] Global Innovative Drug Transactions - A total of 19 significant transactions occurred globally, with four notable deals disclosed [6][43] - Key transactions included a $1.5 billion agreement between Saintgen Biotech and Genentech, and a $388 million deal between Fuhong Hanlin and Eisai [6][43] Market Data - The total market capitalization of the pharmaceutical industry is approximately 53,087.87 billion [11] - The industry P/E ratio (TTM) stands at 37.3, compared to the CSI 300's P/E ratio of 14.0 [11]

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 3.17%, ranking 22nd among 31 primary industries, underperforming the CSI 300 index which fell by 1.25% [6][17] - The valuation of the pharmaceutical and biotechnology industry as of February 6, 2026, is a PE (TTM overall method, excluding negative values) of 29.57x, down from 30.31x in the previous period, indicating a downward trend below the average [6][22] - The top three sub-industries in terms of PE (TTM overall method, excluding negative values) are vaccines (46.30x), hospitals (43.34x), and medical consumables (37.71x), while pharmaceutical distribution has the lowest valuation at 14.88x [22] Industry Trends - The focus in the global pharmaceutical market continues to be on GLP-1 targets, with Eli Lilly's tirzepatide establishing a leading position in the metabolic disease field due to its clinical value and commercialization performance [9] - The collaboration model between multinational pharmaceutical companies and Chinese biopharmaceutical firms is evolving towards "platform capabilities + multi-project combinations," highlighting the long-term strategic value of underlying innovative capabilities such as sustained delivery technology and peptide R&D platforms [9] - The investment logic in the industry is shifting from single blockbuster products to platform-based, matrixed approaches that extend into critical supply chain segments [9] Investment Recommendations - Focus on innovative pharmaceutical companies with "core technology platforms + diversified pipelines," as their ability to derive multiple values from platforms and realize cross-border cooperation milestones will be a key advantage [9] - Pay attention to industry chain segments benefiting from drug long-acting and oral trends, including complex formulation processes, high-end delivery technologies, and related peptide CDMO fields [9] - In the context of strong global R&D and production demand, peptide CXO companies that are active in cross-border collaborations, have balanced customer structures, and possess solid compliance systems will continue to share in the industry's high prosperity dividends [9]